Phase I, multi-center, dose-escalation and dose-expansion study of IMP7068, a WEE1 inhibitor, in patients with advanced solid tumors

被引：2
|
作者：
Lin, C-C. [1 ]
Grewal, J. [2 ]
Baranda, J. C. [3 ]
Schneider, R. E. [4 ]
Zhang, J. [5 ]
Bai, L-Y. [6 ]
Yeh, Y-M. [7 ]
Sommerhalder, D. [8 ]
Li, G. [9 ]
Shen, L. [10 ]
Hsu, H-C. [11 ]
Alese, O. [12 ]
Yin, R. [13 ]
Hsieh, C-Y. [14 ]
Cai, S. X. [15 ]
Tian, Y. E. [16 ]
Xia, H. [14 ]
Li, B. [14 ]
Zhang, M. [14 ]
Zhang, C. [14 ]
机构：
[1] NTUH Natl Taiwan Univ Hosp, Dept Oncol, Taipei, Taiwan
[2] Norton Canc Inst, Med Oncol, Louisville, KY USA
[3] Univ Kansas, Clin Res Ctr, Med Oncol Dept, Kansas City, KS USA
[4] Mary Crowley Canc Res Ctr, Outpatient Evaluat & Treatment Ctr Texas Oncol, Dallas, TX USA
[5] Fudan Univ, Shanghai Canc Ctr, Dept Oncol, Shanghai, Peoples R China
[6] China Med Univ Hosp, Div Hematol & Oncol, New Taipei, Taiwan
[7] NCKUH Natl Cheng Kung Univ Hosp, Oncol, Tainan, Taiwan
[8] NEXT Oncol, Oncol, San Antonio, TX USA
[9] Huazhong Univ Sci & Technol, Tongji Med Coll, Union Hosp, Gynaecol Oncol, Wuhan, Peoples R China
[10] Beijing Canc Hosp, Dept Digest Oncol, Beijing, Peoples R China
[11] Linkou Chang Gung Mem Hosp, Chang Gung Med Fdn, Oncol, Taoyuan, Taiwan
[12] Emory Univ Hosp, Hematol & Med Oncol, 1364 Clifton Rd NE, Atlanta, GA 30322 USA
[13] Sichuan Univ, West China Womens & Childrens Hosp, West China Univ Hosp 2, Dept Oncol & Chemoradiotherapy, Chengdu, Peoples R China
[14] IMPACT Therapeut Inc Shanghai, Clin Dev, Shanghai, Peoples R China
[15] IMPACT Therapeut Inc Shanghai, Dev, Shanghai, Peoples R China
[16] IMPACT Therapeut Inc Shanghai, Res, Shanghai, Peoples R China
来源：
ANNALS OF ONCOLOGY | 2023年 / 34卷
关键词：
D O I：
10.1016/j.annonc.2023.09.1848
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
662MO
引用
收藏
页码：S466 / S466
页数：1
相关论文
共 50 条
  • [41] Phase I Dose-Escalation Study of LCL161, an Oral Inhibitor of Apoptosis Proteins Inhibitor, in Patients With Advanced Solid Tumors
    Infante, Jeffrey R.
    Dees, E. Claire
    Olszanski, Anthony J.
    Dhuria, Shyeilla V.
    Sen, Suman
    Cameron, Scott
    Cohen, Roger B.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (28) : 3103 - +
  • [42] Phase I dose-escalation study of brostallicin in combination with cisplatin (cDDP) in patients with advanced solid tumors
    Lorusso, D.
    Fornari, G.
    Caponigro, F.
    Quirino, M.
    Merlano, M.
    Airoldi, M.
    Schena, M.
    Jannuzzo, M. G.
    Crippa, S.
    Scambia, G.
    EJC SUPPLEMENTS, 2007, 5 (04): : 111 - 112
  • [43] Phase I dose-escalation study of cabazitaxel administered in combination with cisplatin in patients with advanced solid tumors
    A. Craig Lockhart
    Shankar Sundaram
    John Sarantopoulos
    Monica M. Mita
    Andrea Wang-Gillam
    Jennifer L. Moseley
    Stephanie L. Barber
    Alex R. Lane
    Claudine Wack
    Laurent Kassalow
    Jean-François Dedieu
    Alain C. Mita
    Investigational New Drugs, 2014, 32 : 1236 - 1245
  • [44] Phase I dose-escalation study of volasertib in pediatric patients with acute leukemia or advanced solid tumors
    Doz, Francois
    Locatelli, Franco
    Baruchel, Andre
    Blin, Nicolas
    De Moerloose, Barbara
    Frappaz, Didier
    Dworzak, Michael
    Fischer, Matthias
    Stary, Jan
    Fuertig, Rene
    Riemann, Kathrin
    Taube, Tillmann
    Reinhardt, Dirk
    PEDIATRIC BLOOD & CANCER, 2019, 66 (10)
  • [45] A phase I dose-escalation study of Selumetinib in combination with Erlotinib or Temsirolimus in patients with advanced solid tumors
    Jeffrey R. Infante
    Roger B. Cohen
    Kevin B. Kim
    Howard A. Burris
    Gregory Curt
    Ugochi Emeribe
    Delyth Clemett
    Helen K. Tomkinson
    Patricia M. LoRusso
    Investigational New Drugs, 2017, 35 : 576 - 588
  • [46] Phase I dose-escalation study of cabazitaxel administered in combination with cisplatin in patients with advanced solid tumors
    Lockhart, A. Craig
    Sundaram, Shankar
    Sarantopoulos, John
    Mita, Monica M.
    Wang-Gillam, Andrea
    Moseley, Jennifer L.
    Barber, Stephanie L.
    Lane, Alex R.
    Wack, Claudine
    Kassalow, Laurent
    Dedieu, Jean-Francois
    Mita, Alain C.
    INVESTIGATIONAL NEW DRUGS, 2014, 32 (06) : 1236 - 1245
  • [47] Phase I dose-escalation and expansion study of the PARP inhibitor, fluzoparib (SHR3162), in patients with advanced solid tumours
    Li, H.
    Xu, J.
    Shao, B.
    Liu, R.
    Ran, R.
    Song, G.
    Jiang, H.
    Wang, K.
    Shi, Y.
    Liu, J.
    Hu, W.
    Chen, F.
    Zhang, G.
    Wang, Y.
    Zhao, C.
    Ru, J.
    Wang, Q.
    Rugo, H. S.
    Li, G.
    ANNALS OF ONCOLOGY, 2019, 30
  • [48] Phase I Dose-Escalation Study of Intravenous Aflibercept in Combination with Docetaxel in Patients with Advanced Solid Tumors
    Isambert, Nicolas
    Freyer, Gilles
    Zanetta, Sylvie
    You, Benoit
    Fumoleau, Pierre
    Falandry, Claire
    Favier, Laure
    Assadourian, Sylvie
    Soussan-Lazard, Karen
    Ziti-Ljajic, Samira
    Trillet-Lenoir, Veronique
    CLINICAL CANCER RESEARCH, 2012, 18 (06) : 1743 - 1750
  • [49] A phase I dose-escalation study of selumetinib in combination with docetaxel or dacarbazine in patients with advanced solid tumors
    LoRusso, Patricia M.
    Infante, Jeffrey R.
    Kim, Kevin B.
    Burris, Howard A., III
    Curt, Gregory
    Emeribe, Ugochi
    Clemett, Delyth
    Tomkinson, Helen K.
    Cohen, Roger B.
    BMC CANCER, 2017, 17
  • [50] A phase I dose-escalation and pk study of continuous oral rucaparib in patients with advanced solid tumors
    Flynn, M.
    Shapiro, G.
    LoRusso, P.
    Kristeleit, R.
    Patel, M.
    Infante, J.
    Giordano, H.
    Borrow, J.
    Jaw-Tsai, S.
    Burris, H., III
    EUROPEAN JOURNAL OF CANCER, 2013, 49 : S185 - S185
12345